Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COAG NASDAQ:HROW NASDAQ:OCS NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$25.30-0.4%$0.00$23.00▼$36.61$1.18BN/A215,042 shs184,206 shsHROWHarrow$33.19-4.3%$35.93$28.54▼$54.85$1.29B0.281.07 million shs647,781 shsOCSOculis$11.21-5.2%$26.45$11.17▼$34.47$685.96M0.231.10 million shs869,797 shsRCKTRocket Pharmaceuticals$2.75-5.8%$3.44$2.40▼$5.45$318.85M0.482.33 million shs2.55 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-2.90%-9.25%+1.64%+2,540,999,900.00%+2,540,999,900.00%HROWHarrow+4.20%-1.89%-14.27%-4.48%+17.66%OCSOculis-9.97%-60.10%-57.37%-56.12%-38.22%RCKTRocket Pharmaceuticals0.00%-3.31%-17.51%-33.79%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$25.30-0.4%$0.00$23.00▼$36.61$1.18BN/A215,042 shs184,206 shsHROWHarrow$33.19-4.3%$35.93$28.54▼$54.85$1.29B0.281.07 million shs647,781 shsOCSOculis$11.21-5.2%$26.45$11.17▼$34.47$685.96M0.231.10 million shs869,797 shsRCKTRocket Pharmaceuticals$2.75-5.8%$3.44$2.40▼$5.45$318.85M0.482.33 million shs2.55 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-2.90%-9.25%+1.64%+2,540,999,900.00%+2,540,999,900.00%HROWHarrow+4.20%-1.89%-14.27%-4.48%+17.66%OCSOculis-9.97%-60.10%-57.37%-56.12%-38.22%RCKTRocket Pharmaceuticals0.00%-3.31%-17.51%-33.79%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOAGHemab Therapeutics 2.80Moderate Buy$41.7565.02% UpsideHROWHarrow 2.64Moderate Buy$69.43109.19% UpsideOCSOculis 2.80Moderate Buy$38.33241.96% UpsideRCKTRocket Pharmaceuticals 2.38Hold$8.44207.07% UpsideCurrent Analyst Ratings BreakdownLatest RCKT, OCS, HROW, and COAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/1/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.006/1/2026OCSOculis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $38.005/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AHROWHarrow$268.68M4.60$0.86 per share38.55$1.41 per share23.54OCSOculis$1.45M448.25N/AN/A$4.08 per share2.75RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AHROWHarrow-$5.14M-$0.41N/A15.37N/A-5.57%19.59%2.26%8/10/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)Latest RCKT, OCS, HROW, and COAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOAGHemab TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOAGHemab TherapeuticsN/AN/AN/AHROWHarrow10.302.482.30OCSOculis0.015.185.18RCKTRocket Pharmaceuticals0.086.126.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOAGHemab TherapeuticsN/AHROWHarrow72.76%OCSOculis22.30%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipCOAGHemab TherapeuticsN/AHROWHarrow12.80%OCSOculisN/ARCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOAGHemab Therapeutics7246.71 millionN/AN/AHROWHarrow18037.28 million32.50 millionOptionableOCSOculis257.98 millionN/ANot OptionableRCKTRocket Pharmaceuticals240109.19 million85.94 millionOptionableRCKT, OCS, HROW, and COAG HeadlinesRecent News About These CompaniesRocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 5 at 5:01 PM | seekingalpha.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below 200-Day Moving Average - Should You Sell?June 3 at 2:43 AM | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) CEO Gaurav Shah Sells 55,684 SharesMay 27, 2026 | insidertrades.comRocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?May 20, 2026 | finance.yahoo.comRocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6MMay 18, 2026 | finance.yahoo.comInsider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of StockMay 15, 2026 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by AnalystsMay 13, 2026 | marketbeat.comLifesci Capital Analysts Raise Earnings Estimates for RCKTMay 12, 2026 | marketbeat.comSarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 12, 2026 | insidertrades.comRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusMay 11, 2026 | zacks.comRocket Pharmaceuticals (NASDAQ:RCKT) Receives "Buy" Rating from Chardan CapitalMay 11, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings ResultsMay 9, 2026 | marketbeat.comRocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCKT, OCS, HROW, and COAG Company DescriptionsHemab Therapeutics NASDAQ:COAG$25.30 -0.11 (-0.43%) As of 04:00 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Harrow NASDAQ:HROW$33.19 -1.50 (-4.32%) Closing price 04:00 PM EasternExtended Trading$33.25 +0.06 (+0.18%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Oculis NASDAQ:OCS$11.21 -0.62 (-5.24%) Closing price 04:00 PM EasternExtended Trading$11.23 +0.02 (+0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Rocket Pharmaceuticals NASDAQ:RCKT$2.75 -0.17 (-5.82%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.03 (+1.24%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
